Skip to content

Effect of N-acetylcysteine on liver recovery after resection

Effect of N-acetylcysteine on liver recovery after resection: a randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN01624686
Enrollment
460
Registered
2014-08-13
Start date
2007-02-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decrease in liver failure after liver resection for any diagnosis Digestive System

Interventions

Both randomized groups will undergo the same preoperative and intraoperative management. The only difference in postoperative management will be use of N-acetylcysteine infusion - 150 mg/kg of NAC in

Sponsors

Alberta Health Services (Canada)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All adult patients scheduled to undergo major hepatic resection (defined as the removal of at least two Couinaud segments) for any cause at the Foothills Medical Centre who give written informed consent are eligible for the study.

Exclusion criteria

Exclusion criteria: Participation in other trials before or during treatment

Design outcomes

Primary

MeasureTime frame
Overall complication rate. These will be recorded in a prospective fashion throughout the trial. Coding will then be done according to the Clavien-Dindo classification, which is the most common description of types of complications (grade I, II, IIIa, IIIb, IVa, IVb and V).

Secondary

MeasureTime frame
Postoperative liver failure as defined by: 1. The 50-50 criterion (PT>50% (INR>1.7), bilirubin > 50 umol/l (3 mg/dL) on postoperative day 5) 2. Length of stay 3. Postoperative mortality

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026